Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012). (Q38132933)

29 August 2017

title

Indoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012). (English)

1 reference

29 August 2017

Raphaël Frédérick

2

0 references

author name string

Eduard Dolušić

series ordinal

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

30 August 2013

1 reference

Expert Opinion on Therapeutic Patents

29 August 2017

published in

1 reference

29 August 2017

volume

23

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1367-1381

1 reference

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Heme-Containing Oxygenases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Human placental indoleamine 2,3-dioxygenase: cellular localization and characterization of an enzyme preventing fetal rejection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Marrying immunotherapy with chemotherapy: why say IDO?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Tolerance, DCs and tryptophan: much ado about IDO

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Psychological Stress-Induced, IDO1-Dependent Tryptophan Catabolism: Implications on Immunosuppression in Mice and Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Rational design of indoleamine 2,3-dioxygenase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Purification and kinetic characterization of human indoleamine 2,3-dioxygenases 1 and 2 (IDO1 and IDO2) and discovery of selective IDO1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

From inflammation to sickness and depression: when the immune system subjugates the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Kynurenines in the mammalian brain: when physiology meets pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

An expanding range of targets for kynurenine metabolites of tryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Kynurenines in the CNS: recent advances and new questions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.827662

10.1517/13543776.2013.827662

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference